Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Dumontet

Showing results (1-10 of 284) with videos related to

Pageof 29
Sort By:
Haematologica|December 1, 2022
Targeting glutaminase to starve lymphoma cellsCharles Dumontet
Bulletin Du Cancer|November 14, 2008
[Optimising therapy in patients with haematological malignancies]Charles Dumontet
Bulletin Du Cancer|November 27, 2002
[The role of gemcitabine in hematology]Charles Dumontet
Bulletin Du Cancer|October 26, 2011
[Antitubulin agents]Charles Dumontet
Cancer Cell|May 28, 2026
When more target antigen expression is lessCharles Dumontet
Journal of Visualized Experiments : Jove|April 15, 2016
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic AgentsTaghreed Hirz, Charles Dumontet
The Lancet. Oncology|February 2, 2008
Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?Pascal Sève, Charles Dumontet
Current Medicinal Chemistry. Anti-Cancer Agents|February 22, 2005
Chemoresistance in non-small cell lung cancerPascal Sève, Charles Dumontet
Bulletin Du Cancer|March 6, 2007
[Rituximab: mechanism of action and resistance]Stéphane Dalle, Charles Dumontet
Biochimica Et Biophysica Acta|September 21, 2007
Review of recent studies on resistance to cytotoxic deoxynucleoside analoguesLars Petter Jordheim, Charles Dumontet
Pageof 29

Showing results (1-10 of 284) with videos related to

Sort By:
Pageof 29
Haematologica|December 1, 2022
Targeting glutaminase to starve lymphoma cellsCharles Dumontet
Bulletin Du Cancer|November 14, 2008
[Optimising therapy in patients with haematological malignancies]Charles Dumontet
Bulletin Du Cancer|November 27, 2002
[The role of gemcitabine in hematology]Charles Dumontet
Bulletin Du Cancer|October 26, 2011
[Antitubulin agents]Charles Dumontet
Cancer Cell|May 28, 2026
When more target antigen expression is lessCharles Dumontet
Journal of Visualized Experiments : Jove|April 15, 2016
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic AgentsTaghreed Hirz, Charles Dumontet
The Lancet. Oncology|February 2, 2008
Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?Pascal Sève, Charles Dumontet
Current Medicinal Chemistry. Anti-Cancer Agents|February 22, 2005
Chemoresistance in non-small cell lung cancerPascal Sève, Charles Dumontet
Bulletin Du Cancer|March 6, 2007
[Rituximab: mechanism of action and resistance]Stéphane Dalle, Charles Dumontet
Biochimica Et Biophysica Acta|September 21, 2007
Review of recent studies on resistance to cytotoxic deoxynucleoside analoguesLars Petter Jordheim, Charles Dumontet
Pageof 29